Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
418 participants
INTERVENTIONAL
2022-07-07
2025-09-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ARO-APOC3
1 dose of ARO-APOC3 by subcutaneous (sc) injection every 3 months
ARO-APOC3
ARO-APOC3 Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ARO-APOC3
ARO-APOC3 Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing to provide written informed consent
* Completed the 48-week study treatment period in the parent study
Exclusion Criteria
* Any new condition or worsening of existing condition or any other situation that would make the subject unsuitable for enrollment, could interfere with the subject participating in or completing the study, would make it difficult to comply with protocol requirements or put the subject at additional safety risk
* Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arrowhead Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Research Site 1
Beverly Hills, California, United States
Clinical Research Site 2
Northridge, California, United States
Clinical Research Site 3
Palm Springs, California, United States
Clincal Research Site 4
Boca Raton, Florida, United States
Clinical Research Site 5
Fort Lauderdale, Florida, United States
Clinical Research Site 8
Miami, Florida, United States
Clinical Research Site 6
Miami, Florida, United States
Clinical Research Site 9
Miami Springs, Florida, United States
Clinical Research Site 10
Pembroke Pines, Florida, United States
Clinical Research Site 11
Port Orange, Florida, United States
Clinical Research Site 12
Dunwoody, Georgia, United States
Clinical Research Site 13
Minneapolis, Minnesota, United States
Clinical Research Site 14
Tupelo, Mississippi, United States
Clinical Research Site 15
Omaha, Nebraska, United States
Clinical Research Site 16
Las Vegas, Nevada, United States
Clinical Research Site 17
Long Island City, New York, United States
Clinical Research Site 18
New Windsor, New York, United States
Clinical Research Site 19
New York, New York, United States
Clinical Research Site 20
Morehead City, North Carolina, United States
Clinical Research Site 21
Fargo, North Dakota, United States
Clinical Research Site 22
Marion, Ohio, United States
Clinical Research Site 23
Maumee, Ohio, United States
Clinical Research Site 24
Oklahoma City, Oklahoma, United States
Clinical Research Site 25
Greenville, South Carolina, United States
Clinical Research Site 26
Chattanooga, Tennessee, United States
Clinical Research Site 29
Houston, Texas, United States
Clinical Research Site 27
Houston, Texas, United States
Clinical Research Site 28
Houston, Texas, United States
Clinical Research Site 30
San Antonio, Texas, United States
Clinical Research Site 31
Manassas, Virginia, United States
Clinical Research Site 32
Camperdown, New South Wales, Australia
Clinical Research Site 33
Milton, Queensland, Australia
Clinical Research Site 34
Sippy Downs, Queensland, Australia
Clinical Research Site 35
Adelaide, South Australia, Australia
Clinical Research Site 36
Clayton, Victoria, Australia
Clinical Research Site 37
Joondalup, Washington, Australia
Clinical Research Site 38
Nedlands, Washington, Australia
Clinical Research Site 39
Concord, Ontario, Canada
Clinical Research Site 40
London, Ontario, Canada
Clinical Research Site 41
Chicoutimi, Quebec, Canada
Clinical Research Site 43
Montreal, Quebec, Canada
Clinical Research Site 44
Québec, Quebec, Canada
Clinical Research Site 46
Balatonfüred, , Hungary
Clinical Research Site 47
Békéscsaba, , Hungary
Clinical Research Site 48
Debrecen, , Hungary
Clinical Research Site 49
Gyöngyös, , Hungary
Clinical Research Site 50
Komárom, , Hungary
Clinical Research Site 51
Nyíregyháza, , Hungary
Clinical Research Site 53
Amsterdam, , Netherlands
Clinical Research Site 54
Sneek, , Netherlands
Clinical Research Site 55
Zwijndrecht, , Netherlands
Clinical Research Site 58
Papatoetoe, Aukland, New Zealand
Clinical Research Site 56
Christchurch, , New Zealand
Clinical Research Site 57
Christchurch, , New Zealand
Clinical Research Site 59
Bydgoszcz, , Poland
Clinical Research Site 64
Lodz, , Poland
Clinical Research Site 63
Lodz, , Poland
Clinical Research Site 60
Oświęcim, , Poland
Clinical Research Site 61
Poznan, , Poland
Clinical Research Site 62
Rzeszów, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AROAPOC3-2003
Identifier Type: -
Identifier Source: org_study_id